Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial
Clinical and Translational Science · 2026-08 · 19 (8)
DOI: 10.1111/cts.70673 ↗At a glance
Randomisierte kontrollierte Studie in Clinical and Translational Science, published online on 2026-07-26. Written by Ryuzo Hanada and 7 co-authors. Institution: SOUSEIKAI Sumida Hospital, Tokyo, Japan. Major MEDLINE topics: Recombinant Fusion Proteins. Cited 1 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Ferring Pharmaceuticals, Ferring Pharmaceuticals Netherlands.
Abstract (original language)
The first‐in‐class, fully human fusion protein, olamkicept, selectively inhibits trans interleukin‐6 signaling. Previously, the safety, tolerability, pharmacokinetics (PK), and immunogenicity of olamkicept following single ascending doses (SAD) up to 750 mg and multiple ascending doses (MAD) up to 600 mg daily were assessed. To assess higher doses, parallel trials of olamkicept up to 2400 mg daily were separately performed in healthy European and Japanese adult men. In this phase I, single‐center, within‐group randomized, double‐blind trial, Japanese participants were randomized to SAD olamkicept infusions (1200, 1800, and 2400 mg) or placebo. The primary objective was to assess the safety of higher doses of olamkicept based on treatment‐emergent adverse events (TEAEs), vital signs, electrocardiograms (ECG), and clinical chemistry. PK parameters were included as secondary outcomes. Immunogenicity was not assessed in the present Japanese cohort. Twenty‐four participants were randomized. Four TEAEs and no adverse drug reactions were reported. All TEAEs were mild and resolved without intervention. There were no treatment or dose related trends in TEAEs, vital signs, ECG, clinical chemistry, hematology, hemostasis, or urinalysis. A single infusion of olamkicept achieved measurable serum concentrations for up to 28 days after treatment and exposure was dose proportional. In conclusion, single doses of olamkicept up to 2400 mg have a favorable safety profile and dose proportional PK in healthy Japanese men. Trial Registration: ClinicalTrials.gov identifier: NCT06515834
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- SOUSEIKAI Sumida Hospital, Tokyo, Japan.
- Ferring Pharmaceuticals, International PharmaScience Center, Kastrup, Denmark.
- Ferring Pharmaceuticals Co. Ltd., Tokyo, Japan.
ORCID profiles: Katharina Bruzelius, Arjun Ravi, Philippe Pinton
Funding
- Ferring Pharmaceuticals
- Ferring Pharmaceuticals Netherlands
Cite
APA
Hanada, R., Bruzelius, K., Falkenberg, M., Kyhl, L. E., Møgelmose, S., Ravi, A., Pinton, P., & Yoneshima, N. (2026). Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial. Clinical and Translational Science, 19(8). https://doi.org/10.1111/cts.70673
Vancouver
Hanada R, Bruzelius K, Falkenberg M, Kyhl LE, Møgelmose S, Ravi A, et al. Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial. Clinical and Translational Science. 2026;19(8). doi:10.1111/cts.70673
BibTeX
@article{Hanada2026,
author = {Hanada, Ryuzo and Bruzelius, Katharina and Falkenberg, Michael and Kyhl, Lars-Erik and Møgelmose, Signe and Ravi, Arjun and Pinton, Philippe and Yoneshima, Naomichi},
title = {Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {8},
doi = {10.1111/cts.70673}
}
EUVIMED